Deltex Medical manufactures and markets the CardioQ-ODMÔ system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world.
22/05/12
Issue of Equity02/05/12
AGM Statement02/05/12
Result of AGM16/04/12
Holding(s) in Company (Replacement to 10/04/12)16/04/12
Holding(s) in Company
07/03/12
The group is on the cusp of rolling out its CardioQ oesophageal Doppler monitoring (ODM) device on a large scale, and this tender is the latest in a recent string of endorsements for the technology by UK and international health bodies.
06/12/11
The National Health Service’s chief executive has published his intention to instruct the organisation to implement fluid management during surgery using oesophageal Doppler monitoring technogy as a priority. Deltex believes the news is significant for sales of its CardioQ-ODM device
29/09/11
The firm continues to do well with increased sales of its blood monitoring system in the UK, while it is also pursuing opportunities to build recurring revenues in Canada, Scandinavia and Australia
31/05/11
Four separate clinical studies appear to endorse the use of oesophageal doppler monitoring during surgery, lending heavyweight support to the pioneering CardioQ-ODM device created by Deltex Medical Group.
10/05/11
When we last profiled medical device manufacturer Deltex Medical Group in June last year, the shares were trading for around 10.5 pence each. Today, they are some 150% higher at 25.75p. Proactive Investors investigates...
02/05/12
Deltex Medical Group reports increased sales of CardioQ; looks to continued progress04/04/12
Deltex Medical to raise £1.5 million to meet expected new orders29/03/12
Deltex Medical monitor helps reduce complications in abdominal surgery14/03/12
Deltex Medical Group’s CardioQ device performs well in Canadian trials05/03/12
Deltex Medical’s CardioQ endorsed by UK Department of Health
23/11/2011
08/12/2010
Deltex Medical manufactures and sells medical monitors that are used by doctors and nurses to help patients recover more fully and more quickly from the effects of major surgery.
Deltex Medical is a British company, our products are researched, developed, and designed in the UK and are made at our factory in Chichester, West Sussex.
Multiple clinical trials have consistently demonstrated that using our products to ensure that patients receive the right amount of the right fluid at the right time during their surgery (‘Targeted Volume Management’ or ‘TVM’) reduces complications and means that patients can go home sooner than they otherwise would after their operation.
Deltex Medical’s CardioQ™™ monitor is unique in having been proven to be effective in improving patient outcomes and reducing length of hospital stay in repeated, rigorously controlled clinical trials.
To date, more than 300,000 patients have benefited from the use of the CardioQ™ in surgery and in intensive care and our aim is to establish the use of our products as a ‘standard of care’ for all patients undergoing major surgery or needing monitoring in intensive care.
Our products are manufactured to stringent quality standards, in a controlled environment, by trained technicians and are sold in over thirty countries around the world. The CardioQ™ and the probes used with it have an industry-leading track record for reliability and safety.
individualized Doppler Guided Fluid Management
All patients undergoing surgery are at risk from serious and potentially life-threatening complications caused by a reduction in circulating blood volume. This condition, known as hypovolaemia, results from the combined effects of pre-operative fasting, the anaesthetic agent and the blood lost during the surgical procedure. In many respects hypovolaemia can be thought of as akin to severe dehydration.
The complications that hypovolaemia causes arise because the reduced circulating blood volume is unable to carry sufficient oxygen to the major organs and tissues. All of these systems are at risk of failure as a consequence of the resultant oxygen deprivation.
The CardioQ™ monitors the flow of blood leaving the heart with every beat as it happens and consequently can detect any reduction in circulating blood volume early and in real-time. This allows the anaesthetist to intervene quickly and safely to correct the situation, using a combination of specialised fluids and drugs, before the hypovolaemia becomes serious and potentially life threatening. The technique of optimising a patientÕs haemodynamic status in this way, by giving the right amount of the right fluid at the right time, is known as individualized Doppler Guided Fluid Management.
Using the CardioQ™ to monitor and manage a patient’s circulating blood volume during surgery helps them to recover more fully and more quickly. Using the CardioQ™ means that fewer patients need to go to intensive care and those that do tend to stay there for shorter periods. Because patient journeys through the hospital are more predictable and because fewer patients unexpectedly need intensive care support, the CardioQ™ can play an important part in improving the efficiency and productivity of any healthcare system.
For more info on the individualized Doppler Guided Fluid Management CLICK HERE
Clinical Evidence
ODM-guided fluid management has been shown to reduce complications and length of hospital stay after surgery in multiple randomised controlled trials (RCTs) across different types of surgery. Every randomised controlled ODM trial has been positive.
These trials have been subject to a number of meta-analyses and systematic reviews:
* Two meta-analyses re ODM in abdominal surgery published1,2
* One meta-analysis re ODM across all applications published3
* A second meta-analysis re ODM in all settings presented4
* A health technology assessment (HTA) published by ECRI for the Agency for Healthcare Research & Quality (AHRQ)5
* A report by the Centers for Medicare and Medicaid Services based upon the ECRI HTA6
* A report by the UK Centre for Evidence-based Purchasing (CEP)7
* An HTA by the Aberdeen University Health Economic Research Unit commissioned by NIHR8
* A draft HTA re ODM in colorectal surgery by the Spanish government's Entralgo Agency9 and
* Assessment of ODM evidence as Level 1A for abdominal surgery and Level 1B for orthopedic surgery for UK consensus fluid guidelines10
All the above have concluded positively on the benefits of ODM. In effect the AHRQ/ECRI report concluded that, for a large group of surgical patients, no further clinical trials on ODM were necessary.
For further info on Clinical Evidence CLICK HERE
For info on Clinical Evidence CLICK HERE
For info on US Reimbursemen CLICK HERE
Executive Directors of Deltex Medical
Ewan Phillips MA ACA
Position: Chief Executive
Ewan joined Deltex Medical in August 2001 and was appointed Chief Executive in 2009. He has a background in corporate finance and, prior to joining Deltex Medical, was Finance and Strategic Development Director of a technology Company supplying the UK public sector.
Email: eap@deltexmedical.com
Paul Mitchell BSc ACA
Position: Finance Director
Mr Mitchell joined Deltex Medical in August 2002 as Financial Controller, after qualifying as a Chartered Accountant with PricewaterhouseCoopers. In November 2004 he was appointed Company Secretary.
Non-Executive Directors of Deltex Medical
Nigel Keen MA FCA
Position: Chairman
Nigel has been involved with Deltex Medical since 1988, and has been Chairman since 1996. He is Chairman of the Remuneration Committee. Nigel served as Chief Executive from April 2002 to January 2003. He is also Chairman of Axis-Shield plc, The Laird Group plc and Oxford Instruments plc.
Solicitors
Laytons
Carmelite
50 Victoria Embankment
Blackfriars
London
EC4Y 0LS
Nominated Advisor and Broker
Arden Partners
Nicholas House
3 Laurence Pountney Hill
London EC4R 0EU
Principal Bankers
The Royal Bank of Scotland plc
62-63 Threadneedle Street
PO Box 412
London EC2R 8LA
Independent Auditors
PricewaterhouseCoopers LLP
Savannah House
3 Ocean Way
Ocean Village
Southampton
Hampshire SO14 3TJ
Registrars
Capita Registrars
Northern House
Woodsome Park
Fenay Bridge
Huddersfield HD8 0LA
Address
Deltex Medical Group plc, Terminus Road, Chichester, West Sussex, PO19 8TX.
Telephone
+44 1243 774837
Email
cosec@deltexmedical.com
For further contact information CLICK HERE
As at 14 December 2010, the company had been notified of the following holdings of 3% or more of the voting rights of the company (as shareholder and as the direct or indirect holder of financial instruments) pursuant to transitional provision 7 of the DTR Sourcebook of the Disclosure and Transparency Rules:
Gartmore Investment Limited – 10.92%
Herald Investment Management Limited – 6.94%
Charles Stanley & Co Limited – 5.21%
Nigel Keen – 4.24%
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
